Effective Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

Get Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

Effective Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

Effective Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

Effective Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

Effective Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

Effective Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

Effective Relief from Chronic Pain

The TriMED TENS helps to relieve the symptoms of chronic pain that many live with every day.

Read more

FDA Information

We are very pleased to announce that in May, 2014 the FDA officially announced that it will propose approval & reclassification of CES devices for the treatment of insomnia, depression and anxiety from Class III to Class II, which is the same classification as TENS.

http://www.regulations.gov/#!documentDetail;D=FDA-2013-N-0195-0102

There are several steps which must occur before the Agency officially approves CES, including the Agency’s formal proposal for reclassification and the public comment period following such a proposal, but today the Agency stated that is it has determined “that there is sufficient information to establish special controls, and that these special controls, together with general controls, will provide a reasonable assurance of safety and effectiveness for CES devices…FDA plans to issue a proposed order in the future for the reclassification of the CES device into Class II.”

This decision is a watershed moment in the 50 year history of CES and demonstrates that the FDA is committed to supporting scientifically proven alternatives to drug therapy for the treatment of insomnia, anxiety and depression – the three symptoms most common to sufferers of PTS, many of whom served our country in Iraq and Afghanistan. We applaud the Agency’s position and look forward to the months that follow as the regulatory process unfolds.

I believe that this will mean that insurance carriers will no longer be able to classify CES as investigational or experimental because those terms are usually reserved for devices in class III.

Please let me know if you would like any further information.

Therapeutic Resources, INC.

Nancy S. Campbell, President
800-488-8492
nancy@trimedsupply.com